A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia

Starting soon · Phase 1

Conditions studied: Blinatumomab, Revumenib, Lymphoblastic Leukemia, KMT2A-rearranged

In brief

To learn about the safety and effects of revumenib in combination with blinatumomab in patients with newly diagnosed or relapsed/refractory Ph-negative ALL with a KMT2A rearrangement.

Key facts

Study ID
NCT07283640
Run by
M.D. Anderson Cancer Center
People needed
20
Starts
2026-11-18
Expected to finish
2031-08-31
Last updated by the study team
2026-06-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.